Amer M Zeidan1, Mohamed A Kharfan-Dabaja, Rami S Komrokji. 1. aDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland bDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute cDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Abstract
PURPOSE OF REVIEW: Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis. Therefore, novel therapeutic approaches are clearly needed. RECENT FINDINGS: The sequential use of the alternative HMA after failure of first line HMA is associated with modest efficacy. The improved understanding of the biologic underpinnings of the disease have opened the door to study investigational agents that target disrupted molecular pathways critical to the pathogenesis of MDS. Combination treatment strategies using an azacitidine backbone are demonstrating promising early results. Expanding the applicability of allogeneic stem cell transplantation (alloSCT), the only curative modality, by reducing toxicity and relapse rates is another area of active research. SUMMARY: Sequential switching to the alternative HMA, clinical trials of novel targeted therapies, azacitidine-based combination therapeutic strategies, and improvements in the alloSCT platform are the main directions in improving outcomes of MDS post HMA failure.
PURPOSE OF REVIEW: Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis. Therefore, novel therapeutic approaches are clearly needed. RECENT FINDINGS: The sequential use of the alternative HMA after failure of first line HMA is associated with modest efficacy. The improved understanding of the biologic underpinnings of the disease have opened the door to study investigational agents that target disrupted molecular pathways critical to the pathogenesis of MDS. Combination treatment strategies using an azacitidine backbone are demonstrating promising early results. Expanding the applicability of allogeneic stem cell transplantation (alloSCT), the only curative modality, by reducing toxicity and relapse rates is another area of active research. SUMMARY: Sequential switching to the alternative HMA, clinical trials of novel targeted therapies, azacitidine-based combination therapeutic strategies, and improvements in the alloSCT platform are the main directions in improving outcomes of MDS post HMA failure.
Authors: Thomas Prébet; Sylvain Thepot; Steven D Gore; François Dreyfus; Pierre Fenaux; Norbert Vey Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941
Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase Journal: Blood Date: 2012-06-27 Impact factor: 22.113
Authors: Vu H Duong; Michael V Jaglal; Ling Zhang; Vishakha Kale; Jeffrey E Lancet; Rami S Komrokji; Alan F List Journal: Leuk Res Date: 2012-12-27 Impact factor: 3.156
Authors: Mikkael A Sekeres; Ramon V Tiu; Rami Komrokji; Jeffrey Lancet; Anjali S Advani; Manuel Afable; Ricki Englehaupt; Joyce Juersivich; David Cuthbertson; Jennifer Paleveda; Ali Tabarroki; Valeria Visconte; Hideki Makishima; Andres Jerez; Ronald Paquette; Alan F List; Jaroslaw P Maciejewski Journal: Blood Date: 2012-08-22 Impact factor: 22.113
Authors: A M Zeidan; M A Sekeres; G Garcia-Manero; D P Steensma; K Zell; J Barnard; N A Ali; C Zimmerman; G Roboz; A DeZern; A Nazha; E Jabbour; H Kantarjian; S D Gore; J P Maciejewski; A List; R Komrokji Journal: Leukemia Date: 2015-10-14 Impact factor: 11.528
Authors: Luisa Cimmino; Igor Dolgalev; Yubao Wang; Akihide Yoshimi; Gaëlle H Martin; Jingjing Wang; Victor Ng; Bo Xia; Matthew T Witkowski; Marisa Mitchell-Flack; Isabella Grillo; Sofia Bakogianni; Delphine Ndiaye-Lobry; Miguel Torres Martín; Maria Guillamot; Robert S Banh; Mingjiang Xu; Maria E Figueroa; Ross A Dickins; Omar Abdel-Wahab; Christopher Y Park; Aristotelis Tsirigos; Benjamin G Neel; Iannis Aifantis Journal: Cell Date: 2017-08-17 Impact factor: 41.582
Authors: Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Rhett P Katterling; Martin S Tallman; Steven D Gore Journal: Br J Haematol Date: 2014-07-04 Impact factor: 6.998
Authors: Christopher R Cogle; Sandra E Kurtin; Tanya G K Bentley; Michael S Broder; Eunice Chang; Scott Megaffin; Steven Fruchtman; Michael E Petrone; Sudipto Mukherjee Journal: Oncologist Date: 2017-03-10
Authors: Alessandra Romano; Cesarina Giallongo; Piera La Cava; Nunziatina L Parrinello; Antonella Chiechi; Calogero Vetro; Daniele Tibullo; Francesco Di Raimondo; Lance A Liotta; Virginia Espina; Giuseppe A Palumbo Journal: Front Pharmacol Date: 2017-04-26 Impact factor: 5.810